Table 1.
Patient's main clinical characteristics and doses
| Diagnosis | Age | Gender | Dose level | Cell number infused (×108) | NK cells (%) | T cells number infused (x106/kg) | NK cells number infused (x108) | EGFR expression of tumor | Mismatch (Pt vs HD) | Clinical response | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient 1 | Colon cancer | 54 | F | 3.106/Kg | 16.1 | 16 | 0.17 | 2.58 | NA | Bw4- vs Bw4+ | PD |
| Patient 2 | Pancreatic cancer | 63 | F | 3.106/Kg | 7.63 | 19 | 0.14 | 1.45 | + | C1, Bw4+ vs C1C2, Bw4- | Rd |
| Patient 3 | Colon cancer | 50 | M | 3.106/Kg | 11.14 | 21 | 0 | 2.34 | ++ | Bw4- vs Bw4+ | SD |
| Patient 4 | Pancreatic cancer | 54 | M | 8.106/Kg | 13.70 | 37 | 0.22 | 5.07 | ++ | A3/A11- vs A3/A11+ | PD |
| Patient 5 | Colon cancer | 60 | M | 8.106/Kg | 32.80 | 27 | 0 | 8.86 | ++ | Bw4- vs Bw4+ | PD |
| Patient 6 | Colon cancer | 61 | F | 8.106/Kg | 14.11 | 34 | 0.1 | 4.8 | NA | C1, Bw4- vs C2, Bw4+ | PR |
| Patient 7 | Colon cancer | 66 | M | 12.106/Kg | 45 | 26.57 | 0.1 | 11.96 | + | A3/A11- C2 vs A3/A11+ C1C2 | SD |
| Patient 8 | Colon cancer | 62 | M | 12.106/Kg | 24.12 | 29 | 0.01 | 6.99 | +++ | A3/A11- ,C1 vs A3/A11+, C2 | PD |
| Patient 9a | Pancreatic cancer | 53 | M | 12.106/Kg | 20.5 | 16 | 0.164 | 3.28 | NA | A3/A11- vs A3/A11+ | PD |
Abbreviations: F, Female; HD, healthy donor; M, Male; MT, Mutant; NA, Not available; ND, No determined; Pt, patient; PR, partial response; PD, progressive disease; Rd, dissociated response; SD, stable disease; WT, wild-type.
EGFR expression on tumors, + : low , ++ : moderate, +++ : high.
a
Patient 9 received the whole allogeneic NK cell product: 6.24 .106 cells/kg